Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK | Market Cap | 8.82B -26.5% |
| Revenue (ttm) | 812.17M -1.2% |
| Net Income | 25.16M -85.4% |
| EPS | 0.80 -85.3% |
| Shares Out | 31.50M |
| PE Ratio | 350.51 |
| Forward PE | 73.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 132,344 |
| Average Volume | 135,142 |
| Open | 270.00 |
| Previous Close | 267.60 |
| Day's Range | 269.80 - 280.00 |
| 52-Week Range | 160.00 - 338.00 |
| Beta | 1.40 |
| RSI | 81.61 |
| Earnings Date | Apr 24, 2026 |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]
Financial Performance
In 2025, Xvivo Perfusion AB's revenue was 812.17 million, a decrease of -1.25% compared to the previous year's 822.42 million. Earnings were 25.16 million, a decrease of -85.39%.
Financial StatementsNews
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
GOTHENBURG, SE / ACCESS Newswire / March 19, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of th...
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2026 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Ahead of the Annual General Meeting to be held on 27 April 2026, the Nomination Committee p...